0B+
Sequences
0M+
Compounds
0K+
Drugs & Biologics
0M+
Papers
0M+
Patents
0M+
Clinical Trials
Make every biopharma
decision count
Precision AI for early drug discovery, grounded in billion-scale biological and global intelligence data
Explore real research sessions powered by Eureka Life Sciences agents, organized by research workflow
ActRIIA Target Intelligence — Non-Tumor Indications
ACVR2A target intelligence — 7 non-tumor Ab / Fc-fusion assets across PAH, MDS, sarcopenia
Super Agent • Target Intelligence
Pfizer SIK Inhibitor — Top 5 Lead Compound Mining
Pfizer SIK1/2/3 patent — Top 5 sub-nanomolar leads from 53 examples, Lipinski 5/5
Lead Compound
Ivonescimab vs Keytruda — NSCLC Phase 3 Outcomes
H2H clinical outcomes across 4 Ph3 NSCLC trials — mPFS gains, 5 HRs favoring ivonescimab
Super Agent • Clinical Outcome Analysis
Summit Therapeutics — Strategic Positioning Analysis
Bispecific company profile — HARMONi franchise of 6 Phase 3 trials, $20B+ deal stack
Super Agent • Company Profiling
ARO-INHBE — Weight Loss Competitive Advantages
INHBE siRNA analysis — Phase 1/2a data, GLP-1 differentiation, 6-program landscape
Super Agent • Drug Investigation
Inclisiran — U.S. PCSK9 Market Competitiveness
Single-asset PCSK9 analysis — twice-yearly siRNA, −53% LDL-C in VICTORION-INITIATE
Super Agent • Target Intelligence
Optimize candidate, benchmark clinical results, spot market signal.
Lead Compound
Unveil your lead compound to clinical-ready candidates with structured ADMET, biological, and drug-likeness analysis.
Document Analyzer
Analyze complex patent and literature sets with speed and precision. Extract data at scale, compare clinical trial head-to-head findings, and uncover SAR insights with domain-trained models.
Pulse
Stay ahead with customized weekly briefs across your priority targets and indications, including newly published patent alerts, top MNC and biotech activity, lead compound intelligence, and in-depth druggability analysis.
See how biopharma researchers and IP professionals use Eureka LS to accelerate discovery and reduce risk.
The FTO Agent has completely changed our risk management. We can now complete infringement analysis for new products in hours, not weeks. This automation not only saves significant external legal fees but also frees our team from tedious manual screening to focus on critical market entry and risk avoidance strategies.
The Lead Compound Analysis tool has become the essential first gate in our R&D process. Previously, evaluating the novelty and structural risks of a new molecule required days of manual cross-referencing across patent databases; now, we get a comprehensive report in minutes. This automation allows our medicinal chemists to iterate quickly, ensuring we only invest time and resources into the most promising chemical space.
The FTO Agent has completely changed our risk management. We can now complete infringement analysis for new products in hours, not weeks. This automation not only saves significant external legal fees but also frees our team from tedious manual screening to focus on critical market entry and risk avoidance strategies.
The Lead Compound Analysis tool has become the essential first gate in our R&D process. Previously, evaluating the novelty and structural risks of a new molecule required days of manual cross-referencing across patent databases; now, we get a comprehensive report in minutes. This automation allows our medicinal chemists to iterate quickly, ensuring we only invest time and resources into the most promising chemical space.
Challenges you may be facing
Frequently asked questions about Eureka Life Sciences